Related Experiment Video
Updated: Jan 1, 2026
Induction of Endothelial Differentiation in Cardiac Progenitor Cells Under Low Serum Conditions
Published on: January 7, 2019
Cardiac progenitors and paracrine mediators in cardiogenesis and heart regeneration
Nevin Witman1, Chikai Zhou2, Niels Grote Beverborg3
1Department of Cell and Molecular Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden; Department of Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
Insights
Mammalian heart regeneration is challenging. Recent biotechnologies like stem cell therapies show promise for heart repair, but understanding developmental pathways is key for clinical success.
Area of Science:
- Cardiovascular Biology
- Regenerative Medicine
- Developmental Biology
Background:
- Mammalian hearts possess limited regenerative capacity, making heart regeneration a critical goal for treating heart diseases.
- Current challenges in heart regeneration necessitate advanced biotechnologies.
- Recent advancements include stem cell-derived cardiac cells and tissue engineering for preclinical heart repair.
Purpose of the Study:
- To review current knowledge on cardiac progenitor cell biology.
- To discuss major cardiogenic paracrine mediators.
- To explore their roles in cardiogenesis, congenital heart disease, and heart regeneration.
Main Methods:
- Review of recent scientific literature on cardiac progenitor cells.
- Analysis of paracrine mediators in cardiac development and disease.
- Synthesis of findings related to cell-based and cell-free regenerative therapies.
Main Results:
- Biotechnologies like stem cell transplantation and tissue engineering show preclinical efficacy in cardiomyocyte proliferation and heart repair.
- Understanding developmental cellular hierarchies and molecular mechanisms is crucial for optimizing regenerative therapies.
- Cardiac progenitor cell biology and paracrine signaling are key areas for advancing heart regeneration.
Conclusions:
- Despite progress, significant challenges remain in achieving effective mammalian heart regeneration.
- Further in-depth understanding of cardiogenesis is essential for translating preclinical findings into clinical applications.
- Novel cell-based and cell-free therapies hold potential for future heart muscle rebuilding.
Abstract:
The mammalian hearts have the least regenerative capabilities among tissues and organs. As such, heart regeneration has been and continues to be the ultimate goal in the treatment against acquired and congenital heart diseases. Uncovering such a long-awaited therapy is still extremely challenging in the current settings. On the other hand, this desperate need for effective heart regeneration has developed various forms of modern biotechnologies in recent years. These involve the transplantation of pluripotent stem cell-derived cardiac progenitors or cardiomyocytes generated in vitro and novel biochemical molecules along with tissue engineering platforms. Such newly generated technologies and approaches have been shown to effectively proliferate cardiomyocytes and promote heart repair in the diseased settings, albeit mainly preclinically. These novel tools and medicines give somehow credence to breaking down the barriers associated with re-building heart muscle. However, in order to maximize efficacy and achieve better clinical outcomes through these cell-based and/or cell-free therapies, it is crucial to understand more deeply the developmental cellular hierarchies/paths and molecular mechanisms in normal or pathological cardiogenesis. Indeed, the morphogenetic process of mammalian cardiac development is highly complex and spatiotemporally regulated by various types of cardiac progenitors and their paracrine mediators. Here we discuss the most recent knowledge and findings in cardiac progenitor cell biology and the major cardiogenic paracrine mediators in the settings of cardiogenesis, congenital heart disease, and heart regeneration.
